Rezivertinib

(Synonyms: BPI-7711)
1 Cited Publications
Customer Review

Based on 1 publication(s) in Google Scholar

Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib has excellent central nervous system (CNS) penetration and has antitumor activity.

For research use only. We do not sell to patients.

  • Purity: 99.62%
  • CAS No.: 1835667-12-3
  • Formula: C27H30N6O3
  • Molecular Weight:486.57
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need

Publications Citing Use of MedChemExpress (MCE) Rezivertinib

More
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00